Beta-Amyloid Peptides Enhance the Proliferative Response of Activated CD4+CD28+ Lymphocytes from Alzheimer Disease Patients and from Healthy Elderly by Jóźwik, Agnieszka et al.
Beta-Amyloid Peptides Enhance the Proliferative
Response of Activated CD4
+CD28
+ Lymphocytes from
Alzheimer Disease Patients and from Healthy Elderly
Agnieszka Jo ´z ´wik
1¤, Jerzy Landowski
2, Leszek Bidzan
3, Tamas Fu ¨lop
4, Ewa Bryl
1, Jacek M. Witkowski
1*
1Department of Pathophysiology, Medical University of Gdan ´sk, Gdan ´sk, Poland, 2Department of Psychiatry and Neurotic Disorders, Medical University of Gdan ´sk,
Gdan ´sk, Poland, 3Department of Developmental Psychiatry, Psychotic Disorders, and Geriatric Psychiatry, Medical University of Gdan ´sk, Gdan ´sk, Poland, 4Immunology
Program, Geriatric Division, Faculty of Medicine, Research Center on Aging, University of Sherbrooke, Sherbrooke, Quebec, Canada
Abstract
Alzheimer’s disease (AD) is the most frequent form of dementia among elderly. Despite the vast amount of literature on
non-specific immune mechanisms in AD there is still little information about the potential antigen-specific immune
response in this pathology. It is known that early stages of AD include b-amyloid (Ab)- reactive antibodies production and
inflammatory response. Despite some evidence gathered proving cellular immune response background in AD pathology,
the specific reactions of CD4
+ and CD8
+ cells remain unknown as the previous investigations yielded conflicting results.
Here we investigated the CD4
+CD28
+ population of human peripheral blood T cells and showed that soluble b-amyloids
alone were unable to stimulate these cells to proliferate significantly, resulting only in minor, probably antigen-specific,
proliferative response. On the other hand, the exposure of in vitro pre-stimulated lymphocytes to soluble Ab peptides
significantly enhanced the proliferative response of these cells which had also lead to increased levels of TNF, IL-10 and IL-6.
We also proved that Ab peptide-enhanced proliferative response of CD4
+CD28
+ cells is autonomous and independent from
disease status while being associated with the initial, ex vivo activation status of the CD4
+ cells. In conclusion, we suggest
that the effect of Ab peptides on the immune system of AD patients does not depend on the specific reactivity to Ab
epitope(s), but is rather a consequence of an unspecific modulation of the cell cycle dynamics and cytokine production by T
cells, occurring simultaneously in a huge proportion of Ab peptide-exposed T lymphocytes and affecting the immune
system performance.
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Introduction
Although it is clear that Alzheimer’s disease (AD) is a
degenerative brain disorder, the role of immune system in the
disease pathogenesis is indisputable (reviewed e.g. in [1]). AD leads
to irreversible cognitive decline manifesting mainly in memory
impairment, and lately by behavioral changes. Typical changes in
the brain include extracellular deposition of fibrillar 42-aa form of
b-amyloid (Ab1–42) surrounded by dystrophic neurites forming
senile plaques. Inflammation has a direct contribution to
neurodegeneration associated with AD as shown by numerous
epidemiological studies suggesting a potential beneficial anti-
inflammatory intervention [2,3–4]. The initial stage of inflamma-
tion is associated with Ab accumulation, microglia, astrocyte as
well as complement system activation and increased production of
proinflammatory cytokines [5]. Numerous investigations suggest
that it is not only the central nervous system cells (microglia,
astrocytes) that can be blamed for inflammatory response in AD,
but also cells from the periphery, notably including the T
lymphocytes (e.g. [6–8]).
Some of the recent investigations prove that T cells are able to
enter the brain [9], despite a well-grounded knowledge that brain
is an organ protected from systemic immune response. One of the
hypotheses states that because of either a blood-brain barrier
(BBB) damage or in response to signals originating from the cells
being part of the inflammatory response in the brain (both of
which are typical for AD pathology) lymphocytes infiltrate and
accumulate in the places of Ab localization in brain tissue.
Despite previous reports that T cells are able to enter the brain
tissue, it is also possible that T cells exert their effect without
entering the CNS. This action can be performed through T cell-
secreted proinflammatory cytokines and their influence on
microglia and astrocytes, or possibly through T cells promoting
activation of monocytes and/or dendritic cells and consequent
proinflammatory cytokines secretion. Both of these mechanisms
can hypothetically participate in brain inflammation and gliosis
once these proinflammatory cytokines cross BBB. During the
initial stages of AD the immune system activity is directed towards
elimination of b-amyloid, which results in anti-Ab antibodies’
production and inflammatory response. Despite the well-docu-
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and immune dysregulation in AD, a number of questions remain
unanswered concerning the activation state of peripheral T-cells,
subsets of T cells which become activated and the timing of these
events in the course of AD. We have shown before that the
proportion of naı ¨ve to activated terminal memory T cells differs
significantly in mild AD patients [10].
One of the key questions is whether the Ab itself is able to
trigger a specific, significant proliferative response of these cells
which can contribute to the pathogenesis of AD. A number of
investigations have proven positively that Ab can play the role of
antigen for T cells either in AD patients or in healthy people.
Nevertheless, the question if b-amyloid can serve as an antigen for
T cells remains unanswered, as some investigations report that
Ab1–40 does not trigger any proliferative reaction of T cells [11],
and others showed that only T cells of healthy people, including
old and young, are able to react to Ab, whereas those from AD
patients do not exhibit such action [12]. In the recent years, it was
shown with the use of specially designed experiments for detection
of autoreactive T lymphocytes using different Ab peptides for
stimulation (including Ab1–42), that T lymphocytes reactive
against b-amyloid circulate in the peripheral blood and their
number is increasing with age [13]. Therefore previous studies
seem highly inconsistent and haven’t provided definite answer to
the question of Ab antigenicity in AD patients and healthy elderly.
The verification of hypothesis about possible stimulation of T
cells by Ab is especially vital in the context of previous, as it
appeared not entirely successful, attempts to construct an efficient
vaccination directed against b-amyloids. The latter prompted our
hypothesis that, apart from it being an antigen triggering the usual
response, Ab may also exert more general modulatory effect on
the immune system. In order to prove or disprove this hypothesis,
we investigated here the population of peripheral blood
CD4
+CD28
+ cells in order to check its proliferative response to
three different Abs (1–42, 1–40, and 25–35) simultaneously
checking ex vivo their activation phenotype and potential to
produce Th1 and Th2 cytokines in response to b-amyloid.
Materials and Methods
Patients
Samples of peripheral venous blood were obtained from 12 AD
patients aged 52–96 (average 74610) years and 15 age- and sex-
matched controls (average age 6767, range 58–78 years) who took
part in the study.
All patients underwent detailed physical, neurological and
psychiatric examination. Tests of cognitive functions and the
evaluation of general functioning were done. Each of patients had
a routine MRI or SPECT examination performed. Only patients
meeting ICD-10 criteria of AD and criteria of probable AD
according to revised research NINCDS-ADRDA criteria [14]
were included in the study. Patients were subjected to longer
clinical observations, which increased clinical diagnostic accuracy.
Based on MMSE results there were 7 patients with moderate
(MMSE=14–22) and 5 with severe (MMSE,13) intensity of
symptoms. Two of the patients (2/12) were treated with
cholinesterase inhibitors (donepezil) at the time of study and for
at least three months prior, while 10/12 were not treated with the
drugs ever. Neither of the patients or controls had exhibited
features of acute inflammatory process, including elevated ESR,
CRP, or neutrophil count.
Healthy people above the age of 65 years conformed to the
SENIEUR Protocol criteria [15]. All healthy controls underwent
the Mini-Mental State Examination (MMSE) test with the score
from 28–30 [16]. The exclusion criteria for healthy people
included autoimmune diseases, neoplasms and acute or chronic
inflammation. None of the healthy volunteers were taking
medication that would influence the immune system. All
participants were informed about the purpose of the tests and
gave their written informed consent; the project was approved by
the Local Committee for Biomedical Research Ethics at the
Medical University of Gdan ´sk.
Detection of T cell phenotype and activation status by
surface marker staining
Ex vivo phenotype assessment was performed by staining one
hundred microliters of peripheral blood for 30 minutes at room
temperature with combinations of fluorescent FITC-conjugated
anti-CD3, phycoerythrin (PE)-Cy5-conjugated anti-CD4 (both
from DAKO Cytomation, Denmark), PE-conjugated CD28,
CD25, CD69 and HLA-DR (all from Becton Dickinson
Biosciences, USA). Proportions of the CD4
loCD25
high(FoxP3
high)
regulatory T cells (Tregs) were estimated according to [17].
Staining with appropriate, irrelevant, fluorochrome-conjugated
mouse antibodies of the same Ig class (DAKO and BD, as
appropriate) was used as negative (isotype) control. Prior to
analysis, the red blood cells were lysed in erythrocyte lysis buffer
(BD Biosciences, USA) buffer according to manufacturer’s
protocol. The flow cytometry analysis was performed using
FACScan flow cytometer (BD Biosciences, USA). All of the
obtained flow cytometry data was analyzed using Win MDI 2.9
software (J. Trotter, The Scripps Institute, La Jolla, USA).
Assessment of proliferative capabilities of the CD4
+28
+
lymphocytes using the DCT technique
PBMC were isolated by flotation over Histopaque
TM (Sigma-
Aldrich) and washed twice with RPMI-1640 medium (Sigma
Aldrich, USA), containing 100 U/ml penicillin and 100 mg/ml
streptomycin (PS) (Sigma Aldrich, USA). Cells were cultured in
complete culture medium consisting of RPMI-1640 supplemented
with 2 mM L-glutamine, 10% heat-inactivated fetal calf serum
(FCS, Sigma Aldrich, USA), and the PS antibiotics.
For comparison of proliferative dynamic of treated and
untreated lymphocytes the dividing cell tracking (DCT) technique
[18] was adopted. Briefly, six to twelve million separated PBMC
were stained with 2 mM CFSE (carboxyfluorescein diacetate
succinimidyl ester) for 15 min at 37uC and subsequently washed
twice with RPMI/PS mixture. Next, samples of 1 million of
CFSE-stained PBMC were cultured in complete medium, at 37uC
and 5% CO2, and in the presence of either 0.2 or 0.5 mM soluble
amyloid peptides Ab 1–42, Ab 1–40 or a derived neurotoxic
decapeptide Ab 25–35 (Sigma Aldrich, USA). These concentra-
tions were chosen based on the reported concentrations of free Ab
in the physiological fluids and on reported Ab concentrations
affecting cytokine secretion by human T cells in vitro [19,20].
Similar, CFSE-loaded PBMC cultures were stimulated with
immobilized anti-CD3 antibody (125 ng/ml, Becton Dickinson,
USA), alone or in combination with previously listed Ab peptides
at 0.2 mM. In a pilot experiment we have found that neither of the
two soluble Ab concentrations used produced significant increase
in PBMC apoptosis. Unstimulated PBMC cultured in complete
medium were treated as negative control. After 72 and 120 hours
the cells were gathered from the wells, counted, washed with PBS
buffer, stained against CD4 and CD28 antigens with appropriate
fluorochrome-conjugated antibodies listed above and FACS-
analyzed. In the analysis of proliferative response we concentrated
on the CD4
+CD28
+ population, which was appropriately gated
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and untreated CD4
+CD28
+ lymphocytes included the estimation
of actual average number of divisions performed per a dividing
lymphocyte, cell cycle timing and the G0RG1 transition time
[18].
Assessement of influence of the Ab peptides on Th1/Th2
cytokine production in vitro
After 72 and 120 hours of PBMC stimulation with either anti-
CD3 alone or in combination with Ab peptides, culture
supernatants were collected and frozen at 280uC for subsequent
analysis. To assess the production of Th1/Th2 cytokines (IL-2, IL-
4, IL-6, IL-10, TNF-a and IFN-c) by the overall population of
cultured PBMCs, the Cytometric Bead Array (CBA
TM, Becton
Dickinson, USA) was used. Lyophilized cytokine proteins included
in the kit were used to prepare standard curves. 3000 events were
acquired for each sample and later analyzed with the use of Becton
Dickinson (BD) cytometric bead array (CBA) software.
Statistical analysis
Data were analyzed using a non-parametric test for unpaired
(Mann-Whitney U test) or paired (Wilcoxon signed rank test) data.
All statistical analyses were performed with the StatSoft, Inc.
(2008) Statistica
TM data analysis software system version 8.0,
under the Medical University of Gdan ´sk license agreement.
Significance levels are indicated by * when p,0.05, ** when
p,0.005 and *** when P,0.0001 unless mentioned differently in
the legends. K-means clustering was used to subgroup patients and
healthy donors into groups of high and low responders considering
the response towards Ab1–42.
Results
b-amyloid peptides alone do not stimulate significant
proliferation of CD4+ lymphocytes
When challenged in vitro with soluble b-amyloid peptides (Ab1–
42, Ab 1–40, Ab 25–35) only, the gross majority (on average,
above 97%) of CFSE-loaded CD4
+CD28
+ lymphocytes of either
healthy elderly or AD patients did not divide over 120 hours
(Fig. 1). However, a closer scrutiny of the results had shown that,
while Ab peptides did not induce division of any CD4
+CD28
+ cells
of healthy individuals (mean specific % of proliferating cells
0.060.0; Fig. 1, left panel), in the case of patient-derived
lymphocytes some minor (usually below or around 1%),
presumably specific (antigen-driven) proliferation could be seen
in Ab-challenged samples, especially if amyloids were used at
0.5 mM (mean specific % of proliferating cells 0.9660.32; Fig. 1,
right panel). Despite relatively low number of cases (n=5) the
difference in the effect of Abs on healthy and AD lymphocytes was
statistically significant (p=0.017), presumably due to virtual lack
Figure 1. b-amyloid peptides do not stimulate divisions of healthy CD4
+CD28
+ lymphocytes and only weakly those of AD cells in
vitro. CD4
+CD28
+ lymphocyte proliferation was measured with DCT technique as described in Materials and Methods, after stimulation for 120 hours
with Ab 1–40 (A,B,G,H), Ab 1–42(C,D,I,J) or Ab 25–35 (E,F,K,L) at 0.2 or 0.5 mM as indicated. Proportion of dividing cells is given in each histogram as
the net percent of total CD4
+CD28
+ population, obtained by subtracting the observed proportion of proliferating (CFSE-diluting) lymphocytes in
untreated sample from the proportions observed for relevant samples treated with the Abs. Results of an experiment involving paired material from a
healthy, matched control (left panel, gray histograms A–F) and from an AD patient (right panel, black histograms G–L), representative of 5
experiments giving similar picture, are shown.
doi:10.1371/journal.pone.0033276.g001
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CD4
+CD28
+ cells.
b-amyloid peptides significantly modulate proliferation
of anti-CD3-stimulated lymphocytes
PBMC of AD patients and healthy elderly, previously loaded
with CFSE, were treated with immobilized anti-CD3 antibody
alone or in combination with one of the Abs at 0.2 mM. The DCT
assay results clearly show that b-amyloid peptides are able to
enhance the proliferative response of CD4
+CD28
+ lymphocytes to
anti-CD3, significantly increasing the effectiveness of stimulation
by elevating the number of divisions per a dividing CD4
+CD28
+
lymphocyte (Fig. 2 A, B). Comparable results were obtained for
AD patients and healthy elderly individuals, and for all three of the
b-amyloids used: 1–42, 1–40 and 25–35, all of which were
enhancing the proliferative response of CD4
+CD28
+ lymphocytes
to anti-CD3 antibody. No such effect could be seen if the
CD4
+CD28
2 lymphocytes from the same samples were analyzed
(Fig. 3 C, D). Similar results were obtained when 0.5 mM
concentrations of amyloids were used (not shown).
Even though we thus demonstrated the modulatory effect of
every tested b-amyloid for CD4
+CD28
+ cells, we found no
significant differences between AD patients and healthy elderly
volunteers concerning the enhancement of cell cycle parameters
neither in the numbers of divisions per cell nor in other dynamic
features of cell cycle available in the DCT method [18], including
proliferation index, number of cell precursors, the G0RG1
transition time or the percentage of proliferating cells (not shown).
The above might have resulted from our observation that in
both investigated groups (AD vs. healthy elderly) the observed
effects of Ab were grossly individually variable and suggested intra-
group differentiation. Aiming to find possible mechanism(s)
explaining these data we performed cluster analysis and found
two distinct groups, significantly differing in the assessed level of
response (measured as number of divisions per a dividing cell) to
anti-CD3 in combination with either 0.2 or 0.5 mMA b 1–42 after
120 hours of stimulation.
Subject clustering based on different proliferative
responses to modulation by Ab reveals subdivision of
both patients and healthy individuals concerning levels
of T cell activation and cytokine secretion
Accordingly, we clustered the AD patients and healthy elderly
into groups of high and low responders (Fig. 3). While the
numbers of divisions per a CD4
+CD28
+ lymphocyte measured in
the Ab1–42 - treated PBMC from high responders differed
significantly from both low responders and from controls
stimulated with anti-CD3 only (signifying a strong modulatory
effect of the Ab on the lymphocytes of these individuals only), the
number of divisions of ‘low responder’ lymphocytes observed
when Ab 1–42 was present or absent in the cultures did not differ
(Fig. 3 A). Similarly, we have seen a significant shortening of the
cell cycle length only if ‘high responder’ lymphocytes challenged
with the Ab were compared with those stimulated with anti-CD3
only or with ‘low responder’ cells stimulated with both Ab and
anti-CD3 (Fig. 3 B).
Finally, when the productivity of stimulation was assessed by the
proportion of CD4
+CD28
+ cells that underwent at least one
division in the total population of PBMC stimulated over
120 hours, it was significantly higher for ‘high responder’ than
for ‘low responder’ lymphocytes; between 90 and a 100% of the
former divided, while in a half of the latter the relevant proportion
was below 90% and in some was as low as 50–60% only (Fig. 3C).
Thus, significant, multi-faceted, response-enhancing effect of the
Ab could be observed only for high responders. It is worth noting
here that compared to low responders, the high responders’ T cells
respond significantly more vigorously also to anti-CD3 only.
The group of high responders selected on the basis of k-means
clustering included 9 AD patients and 8 healthy elderly whereas
the group of low responders consisted of 3 AD patients and 7
healthy donors. Interestingly, despite apparently higher proportion
of low responders among the healthy, the healthy and AD groups
did not differ significantly in these proportions (Fisher’s exact test,
p=0.69). Also, the average division numbers did not differ
between AD and healthy individuals categorized as high or low
responders (not shown).
It is well known that ageing results in modification of many
properties of the immune cells, including the proportions of
CD4
+CD28
+ lymphocytes. Thus, theoretically, observed differ-
ences between the ‘high’ and ‘low responders’ could be the result
of nonrandom distribution of age and/or proportion of the
CD4
+CD28
+ cells. As shown in the Materials and Methods
section, our subjects’ age range was between 52 and 96 years. Still,
the high responder and low responder groups did not differ
significantly regarding their respective average ages. Also, we did
not see significant correlation between subject ages and any of the
parameters discriminating the high and low responders. Interest-
ingly, high responders exhibited statistically significant, higher
proportion of the CD4
+CD28
2 lymphocytes (thus, reciprocally,
lower proportion of the CD4
+CD28
+ cells) than low responders
(medians 6.44% and 0.61% respectively; Mann-Whitney U test
p=0.046).
Thus, in order to further characterize the high and low
responders, we have analyzed the ex vivo phenotypes of their
CD4
+CD28
+ cells and found that they significantly differed
concerning the expression of activation antigens, including early
expressed CD69 and, especially, the mid-to-late expressed HLA-
DR, percentages of both being significantly higher in the group of
high responders (Fig. 4 A and B). We found no differences between
these two groups concerning another investigated activation
antigen - CD25 (Fig. 4 C). It is noteworthy that the distribution
of results obtained for AD and healthy individuals was random
and homogenous within the ‘high’ and ‘low responder’ groups and
thus it did not allow for their further subdivision according to
‘healthy’ or ‘AD’ status.
After revealing that the CD4
+CD28
+ lymphocytes of high
responders exhibits significantly elevated levels of activation-
related antigens we checked wheather they differed also in Th1/
Th2 cytokine production in response to anti-CD3 plus Ab 1–42.
We found that cultured PBMC of high responders produced
significantly higher levels of TNF-a (Fig. 5 A), IL-6 (Fig. 5 B) and
IL-10 (Fig. 5 C). On the other hand, they made a significantly
reduced level of IFNc (Fig. 5 D). The cells from high responders,
especially those triggered with both anti-CD3 and b-amyloid
peptide, showed also a tendency to make higher amounts of IL-2
and IL-4 compared to low responders; however, the differences
had not reached statistical significance in either case (not shown).
Differing functional (proliferative and secretory) properties of
the CD4
+CD28
+ lymphocytes of high and low responders could
also be the result of different proportion of regulatory T cells
(Tregs) in the two groups. However, the proportions of the
CD4
loCD25
high Tregs did not differ significantly between the high
responder and low responder groups (not shown).
Summary of major differences between high and low responders
is shown in the Table 1.
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Although the disturbances of the immune system and the
presence of systemic inflammation associated to the Alzheimer’s
disease have been widely studied and thoroughly documented in
numerous papers, the understanding of their role in its
pathogenesis is far from complete. The immune system engage-
ment in AD is especially interesting concerning continuing
attempts towards constructing a vaccine aiming to eliminate b-
amyloid, which appeared successful in mice but had dramatic
Figure 2. Proliferative dynamics of CD4
+CD28
+, but not of CD4
+CD28
2 lymphocytes is modulated by b-amyloids. Number of divisions
per (dividing) cell for both healthy elderly (A) and AD (B) CD4
+CD28
+ cells significantly increased, while that of CD4
+CD28
2 lymphocytes (C, D) did not
change after stimulation by anti-CD3 in combination with each of the three b-amyloid peptides at 0.2 mM. Cells were cultured as PBMC, and
CD4
+CD28
+ lymphocytes were gated for DCT analysis based on appropriate phenotype staining as in Materials and Methods. Data are presented as
medians, 25
th and 75
th percentiles and minimal/maximal values obtained for cells stimulated with immobilized anti-CD3 only (white boxes) or with
added Ab 1–42, Ab 1–40, Ab 25–35 (gray boxes for healthy and black ones for AD) as indicated. Statistically significant differences are marked with
*( P=,0,05) or ** (P=,0,01).
doi:10.1371/journal.pone.0033276.g002
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immunization with aggregated b-amyloid 1–42 peptide reduced
cerebral b-amyloid deposition, neuritic dystrophy and gliosis in
amyloid precursor transgenic (APP-tg) mice [21–23] and also
improved cognition [24],[25]. Clinical study in AD patients using
aggregated Ab1–42 in combination with QS21 adjuvant was
halted because of signs of meningoencephalitis in 6% of the
patients [26]. Nevertheless, those patients whose response to
vaccination was positive and resulted in anti-Ab antibodies
production presented slower cognitive decline [27,28]. Further
investigations revealed that two patients with encephalitis had T-
cells infiltrates in the brains which suggest T cell-mediated
immune response as a reason for the adverse events [29,30].
There are hypotheses suggesting persistent stimulation of
immune system by Ab peptides leading to T cell response as well
as to the release of inflammatory mediators and changes in the
activation levels of T cells. In our experimental model we found
that 0.2 or 0.5 mMA b peptides characteristic for AD neuropa-
thology (Ab 1–42 and 1–40) as well as the derived neurotoxic
decapeptide Ab 25–35, are (even if not previously aggregated) by
themselves able to trigger a presumably specific proliferative
response of only a small proportion (around 1%) of CD4
+CD28
+
lymphocytes over up to 120 hours of contact in vitro. This
relatively scarce (but still significant) response was seen only for
patients’ cells and not for those from healthy controls (for whom
the response was virtually null). We have employed the DCT
method based on CFSE staining, enabling to trace specific
proliferation of phenotypically defined cells, while not requiring
separation of cells of interesting phenotype from PBMC mixture
neither prior nor after stimulation [18]. On the other hand,
previous investigations based on
3H-thymidine incorporation as a
method of estimating cells proliferation, proved to be highly
incoherent. Some of them postulate hyper-responsiveness of T
cells from healthy elderly individuals and AD patients in
comparison with middle aged healthy donors [13], while other
claim that there are no significant differences in the ability of T
cells proliferative response to Ab 1–42 in the abovementioned
groups [31] or that T cells of healthy individuals respond to Ab
peptides while those from AD patients do not [32]. Finally, the
authors of some studies show that Ab 1–40 and 1–42 do not
provoke T cell proliferative response [11]. A recent paper by Zota
et al. associates the ability to respond specifically to Ab with the
expression of HLA-DRB1*1501 allele [33]. Although we did not
type the HLA-DR of our subjects, probability that all of the AD
patients were HLA-DRB1*1501 positive, and the controls did not
exhibit this haplotype is extremely low; thus, we suggest that HLA
makeup had no influence on our results. Our observations
employing a technique making possible to distinguish (virtually
‘‘see’’ in the FACS plots) and quantify single dividing lymphocytes
seem to support the ability of CD4
+CD28
+ cells of AD patients to
specifically proliferatively respond to Ab peptide, but at a level not
exceeding that seen for other antigens. This is clearly enough to
elicit also the specific antibody response as seen in Ab vaccination
tests [27,28], even if the increase in IL-4 production by Ab-
challenged lymphocytes that we were able to show was not
significant. We confirmed the proliferative potential of the
investigated AD cells using immobilized anti-CD3 antibody
stimulation and finding no significant difference between the
proliferation dynamics of CD4
+CD28
+ lymphocytes of AD and
healthy elderly individuals. We believe that in our experimental
model employing total PBMC, the antigenic properties of b-
amyloid peptides could be exhibited both through monocyte/
macrophages as antigen presenting cells or directly as it is possible
Figure 3. Healthy and AD individuals can be clustered
according to high or low level of response to modulatory
action of b-amyloids. Comparison of proliferative dynamic parame-
ters of CD4
+CD28
+ cells from individuals clustered according to high
(high responders) and low response to Ab 1–42 (low responders)
Cluster analysis for combined groups of AD patients and healthy elderly
according to enhancement of proliferative response of CD4
+CD28
+ cells
to anti-CD3+Ab 1–42 stimulation was performed as in Materials and
Methods. Highly significant differences between ‘‘high’’ and ‘‘low’’
responders can be observed regarding the numbers of divisions per cell
(A), cell cycle length (B) and the percentages of dividing cells
(C).Relevant p values are shown. Not significant differences are marked
n.s.
doi:10.1371/journal.pone.0033276.g003
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presented by the APCs [34].
The level of reaction elicited by soluble Ab peptides admixed
with anti-CD3-stimulated cultures, compared to stimulation with
anti-CD3 only, seemed to be very variable between investigated
subjects. Based on k-means clustering of proliferation parameters,
we distinguished a group of ‘‘high’’ and ‘‘low’’ responders in both
investigated groups and found that only the high responders’ cells
exhibited significantly activated CD4
+CD69
+ and CD4
+HLA-
DR
+ phenotypes. The difference between high and low responders
was not related to age of individuals included in both groups, or to
the proportion of T regulatory (Treg) lymphocytes. Comparison of
the ability of lymphocytes from high and low responders to
produce the Th1, Th2, and proinflammatory cytokines in vitro
revealed that the high responder cells produced significantly more
TNF-a, IL-6 and IL-10, and significantly less IFNc than low
responders. Lower production of IFNc by high responders’ cells
seems also to fit well with the notion of the role of this cytokine in
stimulating the clearing of Ab deposits [35,36]; thus, high
responders would be at higher risk of amyloid plaque accumula-
tion and, possibly, faster progression of the disease. Such a possible
relation requires further study. Accordingly, we have compared
the results of MMSE test for the AD patients belonging to high
and low responders and found a trend towards lower values in the
high responders (mean MMSE values being 21.869.7 for high and
25.467.4 for low responders), which seems to corroborate our
suggestion of more active disease in the high responders.
TNF-a levels were earlier found to be increased not only in the
brain but also in the cerebrospinal fluid and in the blood plasma of
patients suffering from AD [37–38,39]. Also, a recent study
demonstrated an increased production of IL-6 and IL-10 in mild
cognitive impairment suggesting that immune activation is an
early phenomenon that precedes AD [40]. Contrarily, Schott et al
in their investigations in activated blood cell cultures report
significant decrease of pro- as well as anti-inflammatory cytokines
in AD group and suggests the general decline of immune
responsiveness in AD [41]. Despite seeing significant differences
between the high responder and low responder cells in the
proportions of activated lymphocytes (CD4
+CD69
+, CD4
+HLA-
DR
+) and of CD4
+CD28
2 cells, we cannot attribute decreased
production of IFNc and increased secretion of other proinflam-
matory cytokines by the high responder lymphocytes to these
phenotypic shifts. In particular, observed tenfold increase of the
proportion of CD4
+CD28
2 lymphocytes in high responders
should rather lead to an increase in IFNc production, as these
cells are known to manufacture significant amounts of this
cytokine (e.g. [42,43] ). Thus, we hypothesize that a regulatory
phenomenon occurring in the major, CD4
+CD28
+ population,
possibly due to different response of high- and low responders to
Ab peptides in vivo, is responsible for unusual cytokine secretion
pattern.
Figure 4. Activation status of the CD4
+ lymphocytes of individuals exhibiting high or low response to Ab is different. Percentages of
CD4
+ cells bearing activation markers: CD4
+CD69
+ (A) and CD4
+HLA-DR
+ (B) ex vivo are significantly elevated in the group of high responders (high)
in comparison with low responders (low). No differences exist concerning CD4
+CD25
+ percentage between two investigated groups (C). Data are
presented as medians, 25
th and 75
th percentiles and minimal/maximal values. Statistically significant differences are marked with * (P=,0,05).
doi:10.1371/journal.pone.0033276.g004
Figure 5. Cytokine production in vitro is different for cells of
individuals exhibiting high or low response to Ab. Modified
levels of TNF, IL-10, IL-6 and IFN-c produced by PBMC population in
vitro after stimulation with anti-CD3 and b-amyloid 1–42 in the group of
high vs. low responders. Data are presented as medians, 25
th and 75
th
percentiles and minimal/maximal values as indicated. Statistically
significant differences are marked with * (P,0,01).
doi:10.1371/journal.pone.0033276.g005
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inflammatory and ‘pro-AD’ shift in the reactivity of susceptible
(high responder) cells challenged with Ab which may lay the
ground to otherwise unpredictably higher inflammatory response
seen in some individuals challenged with Ab vaccine. Apparently,
concomitant increase in the level of anti-inflammatory IL-10,
reported also by other studies [44], is not sufficient to alleviate the
inflammatory process happening in the CNS. In our opinion,
successful vaccination in mice could be observed as the
experimental animals were reared in a relatively pathogen-free
environment of ‘specific pathogen free’ animal house; thus, their
immune systems remained at low levels of activity possibly
preventing the generalized modulatory effects of Ab. Contrarily,
human immune system in a typical environment is constantly (sub-
clinically) coping with multiple environmental pathogens, making
it generally more activated. Thus, cells stimulated in vitro with anti-
CD3 would be a better model of actual condition of the typical
human immune system, compared to the murine one.
Our proposed model based on different reactivity of high and
low responders’ lymphocytes to Ab is shown in Fig. 6. It assumes
that in addition to proliferative reaction to the presence of (at least
initially soluble) Ab by the T cells (of AD patients only) specifically
expressing Ab-specific TCR, the amyloid is recognized (and
reacted to) differently by the CD4
+CD28
+ but not CD4
+CD28
2
cells of high and low responders. It is worth mentioning here that
high and low responders differed in the proportion of their
CD4
+CD28
2 lymphocytes, which was significantly lower in the
latter. In our opinion, different proportion of these cells, known to
proliferate less vigorously than CD4
+CD28
+ counterparts and to
exert rather a suppressive and cytotoxic activity, does not
participate in the establishment of high or low responder
phenotype. Thus, T lymphocytes of all AD patients would respond
to Ab specifically, while those of high responders among AD
patients would respond also nonspecifically; cells of healthy elderly
controls would only respond nonspecifically, if an individual
belongs to the ‘high responders’ group. Hypothetical mechanism
of this non-specific immunomodulation can be associated with
direct contact of activated CD4
+CD28
+ cells with soluble Ab
through nonspecific receptors. Their nonspecificity postulated here
excludes the possibility of any role of various HLA haplotypes in
the phenomenon, including HLA-DRB1*1501 shown to be
associated with specific response to Ab [33].
It is worth mentioning here that, although it is the aggregated
Ab which is found in the brain amyloid plaques and causative for
neurotoxicity, it is the soluble (mono- to oligomeric) form that
predominates in the plasma, due to anti-aggregation action of
albumins [45,46]. Thus, soluble forms of Ab would be predom-
inantly in contact with the immune cells outside the brain, making
them more likely to exert modulatory activities postulated and
demonstrated in this work. In fact, most papers where Ab was used
to stimulate the immune cells in vitro utilized its initially soluble
form. Although it cannot be excluded that some Ab aggregation
could happen during the cell culture in both this and other works,
it should be relatively minor due to presence of albumin from
bovine serum constituting a component of the culture medium.
Eventual aggregates, if formed, should be internalized by
monocyte/macrophages present among the PBMC in culture,
then properly elaborated and presented in the context of HLA;
this process should be responsible for the specific response we
recorded (admittedly minor and not different among AD and
healthy individuals).
Potential soluble Ab receptors can be for example the RAGEs
(receptors for advanced glycosylation end products) present on
CD4
+ T cell surface and known to bind various molecules
including the Ab; ligation of RAGE results in cells activation and
inflammatory response [47,48]. One cannot exclude also the role
of TLR4 [49] and possibly oxLDL-R (CD36) [50] in the
phenomenon. TLR-4 receptors are expressed on human CD4+
lymphocytes [51], so their potentially modulatory effect upon
ligation by Ab may even be direct.
An interesting alternate hypothesis, possibly explaining different
behavior of Ab – challenged lymphocytes from high- and low-
responders, arises from recent reports on soluble Ab being bound
by surface-expressed prion precursor protein PrP
c [52,53]. It is
already known for more than a decade, that PrP
c is expressed on
the surface of human peripheral blood lymphocytes (including
CD4
+ cells) and that its expression increases in stimulated
lymphocytes after that of e.g. CD69 and CD25, making the PrP
c
a late activation marker, possibly assuring a fine-tuning of the
immune response by modulating calcium signals during the
activation of cells when triggered with appropriate ligand [54,55].
The latter agrees well with the findings stating increased initial
intracellular calcium levels in T cells from patients with AD set
against age-matched controls [56]. Thus, individuals whose CD4
+
lymphocytes would strongly (for high responders) or weakly (for
low-responders) modulate their proliferative and cytokine-produc-
ing functions when exposed to Ab, should differ in the expression
level of the PrP
c or in the levels of associated signaling. A
likelihood of this hypothesis (admittedly, requiring further studies
to prove or disprove it) is augmented by finding of ageing-
associated increase in the level of PrP
c expression on human
lymphocytes [57] and of its relatively higher expression on
memory as compared to naı ¨ve cells [54]. We have recently shown
significantly increased proportions of memory CD4
+ lymphocytes
circulating in the peripheral blood of AD patients [10]. As (despite
huge range of subjects age in both AD and healthy groups) we did
not see much relation between individual age and high- or low
responder behavior of the T cells, the lymphocytes from high and
low responders could differ in the levels of either of the
Table 1. Major features of high responders and their CD4
+ lymphocytes as compared to low responders.
CLINICAL FEATURES
RESTING PHENOTYPE OF CD4
+
LYMPHOCYTES RESPONSE TO ANTI-CD3 STIMULATION
Proliferation Cytokine secretion
Age MMSE CD28
2 CD25
+ CD69
+ HLA-DR
+ 2Ab +Ab IFNc TNF IL-6 IL-10
High responders vs. low
responders
N.S. Qq N.S. q q qq q Q qq q
Value observed for high responders is shown as significantly higher (q,qq) or lower (Q) than observed for low responders.
N.S. – lack of statistically significant difference between high and low responders.
doi:10.1371/journal.pone.0033276.t001
Soluble Beta-Amyloids and T Cell Proliferation
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33276abovementioned molecules (or any combination of these) due to
e.g. individual genetic makeup.
Expression levels of CD69 of both T-cells and B cells correlated
inversely with the results of Mini-mental Examination Scale tests
in AD subjects, suggesting a direct relation between immune
system activation and the clinical status of patients [58]. Our
results, especially those showing increased activation markers’
expression on the CD4
+ cells of high responders from both healthy
and AD groups, suggest that susceptibility towards activation
induced by anti-CD3 combined with b-amyloid peptides is
associated with initial activation status of CD4
+ cells and not
necessarily with presence of Alzheimer disease itself.
Numerous studies have shown that plasma (soluble to
oligomeric) b-amyloid forms are present in AD subjects as well
as the healthy individuals, with the significantly lowered plasma b-
amyloid 1–42 in demented patients (e.g. [59]). This shows that
soluble Ab is accessible for circulating T cells in AD patients as
well as healthy elderly. Not surprisingly at least some individuals in
both of these groups possess CD4
+CD28
+ cells reacting by an
enhanced proliferative response through continuous contact with
Ab as an endogenous, chronic stimulus. Interestingly, this up-
modulation is limited to the ‘high responder’ subgroup that we
propose and irrespective of the AD status.
In conclusion, our results seem to show that individuals differ
in the susceptibility of their CD4
+CD28
+ lymphocytes to the
modulatory effect of Ab in their response to stimulation. The
proportion of those who are susceptible (our ‘high responders’
does not vary significantly between the AD and clinically
healthy cohort. Whether the high responder status may be
explanatory for AD pathogenesis and progression or have a
predictive value in prediction or early diagnosis of AD remains
to be shown.
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